CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
Intravenous Glycoprotein inhibitor + ASA, Clopidogrel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01103440
NCT01103440Phase 2Completed
CompareCT.gov

A Randomized, Pilot, Single-center Study, Investigator-Initiated Study to Look at an Aggressive Therapeutic Approach in Aspirin Resistant Patients Comparing to Standard for Patient Undergoing Percutaneous Coronary Intervention

Icahn School of Medicine at Mount Sinai·interventional·Posted Apr 14, 2010·Updated Feb 14, 2018

In Brief

A Phase 2 clinical trial evaluating Intravenous Glycoprotein inhibitor + ASA, Clopidogrel and Antiplatelet Therapy (ASA, Clopidogrel) for Stable Angina. Completed, enrolled 36 participants across 1 site.

Detailed Summary

The objective of this study is to evaluate if aggressive antiplatelet therapy would reduce ischemic events in aspirin (ASA) resistant patients after percutaneous coronary intervention (PCI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStable Angina
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 14, 2010
Enrollment StartApr 1, 2007
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 16.2 years ago

Interventions

Intravenous Glycoprotein inhibitor + ASA, Clopidogreldrug

IV Glycoprotein IIb/IIIa inhibitor bolus intra procedurally

Antiplatelet Therapy (ASA, Clopidogrel)drug

Standard antiplatelet PCI treatment